In the BioHarmony Drug Report Database

"Preview" Icon

Roflumilast

Daliresp, Daxas (roflumilast) is a small molecule pharmaceutical. Roflumilast was first approved as Daliresp on 2010-07-05. It is used to treat chronic obstructive pulmonary disease in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against cAMP-specific 3′,5′-cyclic phosphodiesterase 4B. In addition, it is known to target cAMP-specific 3′,5′-cyclic phosphodiesterase 4D. Daliresp’s patents are valid until 2024-03-08 (FDA).

 

Trade Name

 

Daxas
 

Common Name

 

roflumilast
 

ChEMBL ID

 

CHEMBL193240
 

Indication

 

chronic obstructive pulmonary disease
 

Drug Class

 

Antiasthmatics/antiallergics: type IV phosphodiesterase inhibitors

Image (chem structure or protein)

Roflumilast structure rendering